

Opioids Prior Authorization Request Form (Page 1 of 3)
 DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
<p>Select the diagnosis below:</p> <input type="checkbox"/> Acute pain (less than 90 days) <input type="checkbox"/> Cancer Pain, Hospice Care, Palliative Care, or Treatment in a Long-Term Care Facility <input type="checkbox"/> Chronic pain (90 days or greater) <input type="checkbox"/> Post-operative pain <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
<p>Acute pain (less than 90 days) or post-operative pain:</p> <p>Is the patient's Active Daily morphine milligram equivalent (MME) greater than or equal to 120? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, select if the prescriber attests to the following:</p> <input type="checkbox"/> He/she acknowledges the warnings associated with high dose opioid therapy including fatal overdose, and that therapy is medically necessary for this patient <input type="checkbox"/> He/she has prescribed naloxone <input type="checkbox"/> He/she has reviewed the Virginia BOM Regulations for Opioid Prescribing <input type="checkbox"/> He/she will be managing the patient's opioid therapy long term <p>Has a benzodiazepine been filled in the past 30 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, select if the prescriber attests to the following:</p> <input type="checkbox"/> He/she has counseled the patient on the FDA black box warning on the dangers of prescribing Opioids and Benzodiazepines including fatal overdose <input type="checkbox"/> He/she has documented that the therapy is medically necessary <input type="checkbox"/> He/she has recorded a tapering plan to achieve the lowest possible effective doses of both opioids and benzodiazepines per the Board of Medicine Opioid Prescribing Regulations <p>Has Naloxone been prescribed for patients with risk factors of prior overdose, substance use disorder, doses in excess of 120 MME/day, or concomitant benzodiazepine? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>					
<p>Cancer Pain, Hospice Care, Palliative Care, or Treatment in a Long-Term Care Facility:</p> <p>Does the prescriber attest that the patient has intractable pain associated with ONE of the following: Active cancer, hospice care, OR palliative care (treatment of symptoms associated with life limiting illnesses)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is the patient in remission from cancer and the prescriber is safely weaning patient off of opioids with a tapering plan? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is the patient in a long-term care facility? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>					

Opioids Prior Authorization Request Form (Page 2 of 3)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Chronic pain (90 days or greater):

Does the prescriber attest that a treatment plan with goals that address benefits and harm has been established with the patient and there is a SIGNED AGREEMENT with the patient? Yes No

Please note: This will be reviewed with the patient within 1 to 4 weeks of starting opioid therapy for chronic pain, with dose escalation and is reviewed every 3 months or more frequently

Has the prescriber ordered and reviewed a urine drug screen (UDS) or serum medication level per the following requirements: If initiating treatment, prior to initiation; OR If maintaining treatment, at least every 3 months for the first year of treatment and at least every 6 months thereafter to ensure adherence? Yes No

Select the following drugs, covered without Prior Authorization, the patient has tried and failed:

- | | | |
|--|---|--|
| <input type="checkbox"/> Baclofen | <input type="checkbox"/> Gabapentin/Lyrica | <input type="checkbox"/> Non-steroidal anti-inflammatory drugs (NSAIDs) (oral) |
| <input type="checkbox"/> Capsaicin gel | <input type="checkbox"/> Lidocaine 5% patch | <input type="checkbox"/> Tricyclic antidepressant (e.g., nortriptyline) |
| <input type="checkbox"/> Duloxetine | | |

Is the patient established on a long-acting opioid? Yes No

*** Please note: Chart documentation of the above is required to be submitted along with this fax*

Is the patient's Active Daily morphine milligram equivalent (MME) greater than or equal to 120? Yes No

If **yes**, select if the prescriber attests to the following:

- He/she acknowledges the warnings associated with high dose opioid therapy including fatal overdose, and that therapy is medically necessary for this patient
- He/she has prescribed naloxone
- He/she has reviewed the Virginia BOM Regulations for Opioid Prescribing
- He/she will be managing the patient's opioid therapy long term

Has a benzodiazepine been filled in the past 30 days? Yes No

If **yes**, select if the prescriber attests to the following:

- He/she has counseled the patient on the FDA black box warning on the dangers of prescribing Opioids and Benzodiazepines including fatal overdose
- He/she has documented that the therapy is medically necessary
- He/she has recorded a tapering plan to achieve the lowest possible effective doses of both opioids and benzodiazepines per the Board of Medicine Opioid Prescribing Regulations

Has Naloxone been prescribed for patients with risk factors of prior overdose, substance use disorder, doses in excess of 120 MME/day, or concomitant benzodiazepine? Yes No

For non-preferred opioids, also answer the following:

Short-Acting non-preferred products include: Nucynta, Opana, Oxaydo, Primlev, Trezix

Long-Acting non-preferred products include: Arymo ER, Belbuca, Butrans (buprenorphine patch), Embeda, Exalgo, Hysingla ER, Nucynta ER, Opana ER, Oxycodone ER, OxyContin, Xartemis XR, Xtampza ER, Zohydro ER

Has the patient had an adequate trial and failure of THREE different preferred generic opioids? Yes No

If **yes**, please specify all: _____

Quantity limit requests:

What is the quantity requested per DAY? _____

Previous therapies failed and/or therapies currently used in combination with the requested medication (*List ALL medications tried or authorization process will be delayed*):

Is the prescribed dose higher than the maximum dose recommendation in FDA-approved labeling (i.e., the package insert)? Yes No

If **yes**, please provide documentation to support the safety and efficacy of the higher dose (such as evidence from practice guidelines or clinical trials from peer-reviewed medical literature).

*** Please note: Documentation of the above is required to be submitted along with this fax*

****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.****

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

Prescriber Signature: _____ Date: _____

Opioids Prior Authorization Request Form (Page 3 of 3)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-800-711-4555.
This form may be used for non-urgent requests and faxed to 1-800-527-0531.